President Donald Trump put the pharmaceutical industry on notice early Monday with the signing of his "most favored nation" (MFN) executive order on drug prices. The order seeks to tie U.S. prices to significantly lower costs overseas.
Many questions remain about how the measure will be implemented, and legal challenges are almost certain. To assess the seriousness of the threat, Fierce Pharma assembled a team of reporters and editors to break down the executive order and the industry’s response.
After examining the MFN executive order, the group dives into other recent policy developments in Washington, D.C., and beyond, including tariffs, Medicare drug price negotiations and more.
To learn more about the topics in this episode:
- Trump signs sweeping executive order to cut US drug prices by 'up to 90%'
- Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations
- As Trump threatens tariffs on drugs, industry warns EU of $100B-plus pharma exodus to US
- US net drug spending surged 11.4% last year, boosted by obesity and oncology meds: IQVIA